問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Division of Urology

Division of Thoracic Medicine

National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of Hematology & Oncology

National Taiwan University Cancer Center (在職)

Division of Hematology & Oncology

Division of Hematology & Oncology

更新時間：2025-09-17

林家齊Lin, Chia-Chi
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

Recruiting Trial

377Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林家齊

List

688Cases

2023-08-01 - 2028-03-15

Phase I

Active
FONTANA: A Modular Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors.

  • Condition/Disease

    Ovarian Cancer、 Lung Adenocarcinoma

  • Test Drug

    AZD5335 AZD5305

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2021-10-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting2Sites

Recruiting6Sites

2020-06-26 - 2026-12-31

Phase I/II

Active
A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants with HER2-Overexpressing Gastric Cancer (DESTINY-Gastric03)

  • Condition/Disease

    HER2 overexpressing locally advanced or metastatic, unresectable Gastric Cancer.

  • Test Drug

    Trastuzumab Deruxtecan

Participate Sites
6Sites

Recruiting6Sites

2015-10-01 - 2020-06-30

Phase III

Completed
A Phase III, Randomized, Open-label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Unresectable Stage IV Urothelial Bladder Cancer

  • Condition/Disease

    Urothelial Bladder Cancer

  • Test Drug

    MEDI4736; Tremelimumab

Participate Sites
6Sites

Recruiting3Sites

Terminated3Sites

馮思中
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2023-02-01 - 2026-12-31

Phase I

Active
A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Immunotherapy With or Without Carboplatin in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (Tropion-Lung04)

  • Condition/Disease

    Advanced or Metastatic NSCLC

  • Test Drug

    凍晶注射劑 注射劑 注射劑 注射劑 注射劑

Participate Sites
7Sites

Recruiting7Sites

2022-01-01 - 2031-02-27

Phase III

Active
A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    Durvalumab Oleclumab Monalizumab

Participate Sites
8Sites

Recruiting8Sites

2018-09-28 - 2026-12-31

Phase III

Active
A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer

  • Condition/Disease

    Muscle-Invasive Bladder Cancer

  • Test Drug

    Durvalumab

Participate Sites
8Sites

Recruiting6Sites

Terminated1Sites

2023-07-01 - 2026-09-30

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2014-08-01 - 2020-12-31

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2017-05-01 - 2020-07-31

Phase III

Active
A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Small-Cell Lung Cancer (NSCLC) (POSEIDON)

  • Condition/Disease

    Non Small-Cell Lung Cancer (NSCLC)

  • Test Drug

    Durvalumab / Tremelimumab

Participate Sites
10Sites

Recruiting1Sites

Terminated9Sites

羅永鴻
Taipei Veterans General Hospital

Division of Thoracic Medicine

1 8 9 10 11 12 69
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB